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Abstract
Methylated DNA immunoprecipitation followed by high-throughput sequencing (MeDIP-seq) has the potential to identify
changes in DNA methylation important in cancer development. In order to understand the role of epigenetic modulation in
the development of acute myeloid leukemia (AML) we have applied MeDIP-seq to the DNA of 12 AML patients and 4 normal
bone marrows. This analysis revealed leukemia-associated differentially methylated regions that included gene promoters,
gene bodies, CpG islands and CpG island shores. Two genes (SPHKAP and DPP6) with significantly methylated promoters
were of interest and further analysis of their expression showed them to be repressed in AML. We also demonstrated
considerable cytogenetic subtype specificity in the methylomes affecting different genomic features. Significantly distinct
patterns of hypomethylation of certain interspersed repeat elements were associated with cytogenetic subtypes. The
methylation patterns of members of the SINE family tightly clustered all leukemic patients with an enrichment of Alu
repeats with a high CpG density (P,0.0001). We were able to demonstrate significant inverse correlation between
intragenic interspersed repeat sequence methylation and gene expression with SINEs showing the strongest inverse
correlation (R2 = 0.7). We conclude that the alterations in DNA methylation that accompany the development of AML affect
not only the promoters, but also the non-promoter genomic features, with significant demethylation of certain interspersed
repeat DNA elements being associated with AML cytogenetic subtypes. MeDIP-seq data were validated using bisulfite
pyrosequencing and the Infinium array.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous form of cancer
in which many molecular and cytogenetic somatically acquired
events have been described [1]. Although these somatic changes
have considerable influence over clinical outcome and constitute
valuable biomarkers for disease classification [2] their role in the
evolution of the stem cell to a fully transformed leukemic cell has yet
to be completely understood. It is clear that some of the genes altered
in AML play key roles in epigenetic regulation both at the DNA and
chromatin levels. The MLL gene is involved in many chromosomal
translocations in leukemia [3] and can also be altered by partial
tandem duplication. This gene is now recognized as a histone
methyltransferase. The EZH2 gene, which encodes a histone
methyltransferase, is subject to inactivating monoallelic and biallelic
mutations in myelodysplastic/myeloproliferative neoplasms [4]. The
potential significance of DNAmethylation changes in AML has been
given further emphasis with the recent discovery of somatic
mutations in DNMT3A, which encodes a DNA methyltransferase
[5]. There is therefore a considerable body of evidence that
implicates epigenetic alterations as being important in the
development of AML [6]. However, in order to fully understand
the role of DNA methylation in AML, a global view of the AML
methylome is required.
MeDIP (methylated DNA immunoprecipitation) is one of the
main approaches for detection of DNA methylation [7]. The
introduction of next generation sequencing extends the study of
DNA to yield whole genome methylation analysis [8]. MeDIP-seq
(MeDIP followed by high-throughput sequencing) can investigate
the entire genome in an unbiased manner in contrast to array-based
methods, which analyze pre-identified sequences [9,10]. We
therefore used this approach to develop whole-genome DNA
methylation profiles with a view to the identification of epigenetic
features relevant to the development of AML and some of its
subtypes. We mapped complete methylomes from 12 AML samples
including 4 different cytogenetic subtypes [1] and from 4 normal
bone marrows (NBMs) using antibody-mediated enrichment of
methylated DNA. Using a previously published method (Batman
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algorithm) [11,12], we were able to construct 100 bp resolution
methylation map for each leukemia and NBM. That enabled us to
identify significant methylation differences in the promoters, the
non-promoter genomic regions and also in repeat elements.
Results
In order to perform a genome wide analysis of DNA
methylation in AML, we applied the MeDIP-seq technique to
DNA samples from 12 AML patients: 3 with t(8;21) translocation,
3 with the t(15;17) translocation, 3 with trisomy 8, and 3 with a
normal karyotype (NK). We used 4 unrelated NBMs as control
samples (Table S1). A total of 7.66108 reads were generated of
which 53% could be mapped uniquely to the reference human
genome (NCBI 36/hg18). The coverage of the 27 million CpG
sites in the reference genome ranged from 63% to 87% for the 16
datasets (Table S2). Furthermore, the saturation analysis indicated
that sufficient numbers of reads had been obtained to generate
reliable methylome profiles for each DNA sample (Fig. S1) [13].
For interpretation of DNA methylation signals, we used the
Batman algorithm [11,12], which takes into account the
underlying CpG density to obtain quantification of methylation
(scores being given in the range 0–1). MeDIP-seq results were
validated by both the Illumina Infinium array platform and
bisulfite pyrosequencing of individual regions (see below). Three
DNA samples (studies No. 11, 12 and 13) were analyzed on the
Illumina HumanMethylation 27 BeadArray. The methylation
levels at 27,578 CpG sites of the array were compared to
equivalent values from MeDIP-seq results. Strong correlations
between both methods were found (R2= 0.89, 0.9 and 0.8
respectively) (Fig. S2). These correlations between MeDIP-seq
and Infinium array are consistent with and slightly higher than
previously reported correlations between both methods (R2= 0.8)
[12].
Global DNA methylation assessment in AML and NBM
Firstly, we analyzed AML and NBM whole genome data to
assess the significance of differences in global DNA methylation.
We categorized DNA methylation into 5 groups; ,0.2, 0.2–0.4,
0.4–0.6, 0.6–0.8, 0.8–1.0 Batman scores [11] (Fig. 1A). Fisher’s
exact test did not demonstrate significant difference in global DNA
methylation between all AMLs and all NBMs (P= 0.96). There
was only 2.68% difference in the global DNA methylation; AML
DNA methylation average was 67.68% while for NBM DNA
Figure 1. Global DNA methylation display in AML and NBM. (A) DNA methylation of all AML patients and all NBMs were categorized into 5
groups of methylation. There was no significant difference in the global DNA methylation between AML and NBM. (B) DNA methylation scores of all
AMLs (blue line) and all NBMs (green line) were plotted against their density (frequency). AML has less frequency of DNA methylation scores.0.8 in
the comparison with NBM. (C–J) Percentages of different groups of DNA methylation in the average of each triplicate of AML subtype and in the
average of 4 NBMs. SINEs showed the highest difference in the DNA methylation scores.0.8 between NBM and AML.
doi:10.1371/journal.pone.0033213.g001
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methylation average was 70.36%. The frequency of Batman
scores.0.8 was less in AML than in NBM as some regions of the
genome i.e. gene bodies and repeated DNA sequences lose their
DNA methylation in cancer (global hypomethylation) [14]
(Fig. 1B). To investigate this further, the genome was subdivided
into 4 features; promoters, gene bodies, CpG islands (CGIs), and
CGI shores (description for each genomic region is summarized in
Table S3) and 4 repeat classes (satellites, SINEs; short interspersed
nuclear elements, LINEs; long interspersed nuclear elements, and
LTRs; long terminal repeats) (Figs. 1C–J). Among these features,
gene bodies (Fig. 1D) exhibited the highest level of DNA
methylation (82% in AML and 85% in NBM having a Batman
score.0.6). The difference in the percentages between AML and
NBM is consistent with the global hypomethylation that is a
feature of cancer [15]. By contrast, CGIs (Fig. 1E) showed the
lowest levels of DNA methylation (16% in AML and 13% in NBM
having a Batman score.0.6). CGIs are generally protected from
being methylated in normal tissues, whereas in malignancy some
CGIs are targets for DNA methylation [6]. Global hypomethyla-
tion in AML was mainly observed in SINEs since we noted that
,20% fewer SINE repeats in AML with a Batman score.0.8
(Fig. 1H). SINEs, especially the Alu family, are rich in methylated
CpGs and are common targets for DNA methylation in normal
tissues [16].
Methylation of localized genomic regions discriminates
AML and its subtypes
Next, we investigated whether methylation of specific genomic
features could discriminate between AML and NBM. Conse-
quently, we searched for differentially methylated regions (DMRs)
in 4 genomic categories; promoters, gene bodies, CGIs and CGI
shores using empirical Bayes statistics (Bioconductor’s Limma R
package). This analysis indicated that 105 gene promoters and 704
CGIs showed significant differences in methylation between AML
and NBM (Table S4). 80% of differentially methylated CGIs were
located outside the promoters (within the gene bodies or
intergenically located) with a 2-fold increase in the number of
differentially methylated CGIs located within the promoters
between NBM and AML (Dataset S1, S2, S3, S4). In order to
identify which genomic feature is the strongest predictor, we
performed a two-dimensional cluster analysis (Figs. 2A–D) and a
pair-wise comparison (Fig. S3) that indicated, of the 4 genomic
features, the CGIs could cluster all the AML samples most tightly
and discriminate them from NBM. In order to estimate the
strength of this clustering, we have applied a prediction strength
algorithm [17], which indicated very high stability of AML and
NBM clusters (Fig. S4). Moreover, the examination of the
differentially methylated promoters (Dataset S1) identified some
previously noted targets for epigenetic silencing or alteration in
Figure 2. Hierarchical clustering of AML versus NBM in 4 genomic features. First row represents cluster analysis of all AMLs versus all NBMs
and the second row represents cluster analysis of AML subtypes in promoters (A, E), gene bodies (B, F), CGIs (C, G) and CGI shores (D, H). In each
figure, each column represents AML patient/NBM and each row represents a single DMR. AML patients were clustered more tightly in CGIs (first row).
t(8;21) AML subtype was clustered separately from the other AML subtypes (second row).
doi:10.1371/journal.pone.0033213.g002
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hematological disorders. For example, ID4 has been shown to act
as a putative tumour suppressor gene in AML [18], DCC is
hypermethylated in follicular lymphoma [19] and mutation of
TERT increases the risk of familial AML [20]. This gene list also
included genes that have roles in a variety of other cancers e.g.
DPP6 is down regulated in melanoma [21], SPHKAP plays a role in
the sphingosine phosphorylation pathway that induces tumor
progression and invasion [22,23]. Additionally, differentially
methylated gene bodies, intragenic CGIs (within promoters/gene
bodies) and intragenic CGI shores identified a number of genes
belonging to potentially important transcription factor families e.g.
MYOD1, SOX14, FOXA2, FOXB2, RUNX1 and PAX1.
We included AML patients with 4 cytogenetic subtypes so that we
could detect DMRs that would discriminate between each subtype.
The highest number of DMRs separating an AML subtype from the
rest of groups was found in t(8;21) AML. By contrast, trisomy 8
AML showed the lowest number of identified DMRs. Most of total
DMRs in each AML subtype were hypermethylated (,60% of total
DMRs) except in trisomy 8 AML where only 40% of total identified
DMRs were hypermethylated. For all AML subtypes, the
hypermethylated DMRs was located mostly in CGIs where the
preferential methylation was found in CGIs located outside the
promoters (within the gene bodies or intergenically located) (Table
S5). Additionally, there were very few DMRs that overlapped
between AML subtypes with no common hypo or hypermethylated
DMRs between the all 4 AML subtypes (Fig. S5). Most of those
DMRs are unique for each AML subtype i.e. DMRs associated with
MEIS1/2, TOP3B, CDH13, ST6GAL2 in t(8;12) AML, DOK6,
NCOR2 in t(15;17) AML, ELK1, VMO1 in NK AML, SNX16,
HHEX in trisomy 8 AML. Based on a two-dimensional cluster
analysis (Figs. 2E–H) and a pair-wise comparison (Fig. S6) AML
subtypes could be readily distinguished using the identified genomic
features with a notable clustering of t(8;21) subgroup distantly from
the other AMLs.
Distinctive pattern of repeat sequence methylation in
AML
A considerable advantage of high-throughput sequencing is the
ability to investigate repeated elements, which would cross-
hybridize on a microarray chip [24]. The uniquely mapped reads
were used to determine the methylation patterns on repeated
sequences [12,25]. We identified numbers of interspersed elements
associated DMRs between AML and NBM (Table S6, Dataset S5,
S6, S7). The methylation pattern of the selected SINEs, LINEs
and LTRs could readily discriminate AML from NBM (Figs. 3A–
C, Fig. S7). The clearest distinction between AML and NBM was
obtained with SINE methylation; 62% of those SINEs were of the
Alu class (43% AluJb, 40% AluSx). These discriminating repeats
had a significantly high CpG density compared with the rest of the
Alu subfamilies (P = 0.002) and with the rest of SINEs (P,0.0001).
An examination of the cytogenetic subtype specific repeat
sequence methylation is shown in Figs. 3D–F & Fig. S8. It was
evident that for LINEs, SINEs and LTRs the feature that
discriminated AML subgroups was hypomethylation of particular
groups of repeats. Most of those distinctive hypomethylated
repeats were intergenic in LTRs and in LINEs (,65% found in
LINE1). However, most of the distinctive hypomethylated SINEs
belonged to the Alu family and were intragenically located. For
satellites, few repeats were found differentiating AML from NBM
and discriminating between AML subtypes.
MeDIP-seq data validation
MeDIP-seq data were validated by 2 approaches: genome-wide
using HumanMethylation 27 BeadArray (Fig. S2) and also by
locus-specific methods on selected DMRs. For locus-specific
validation, we performed direct bisulfite sequencing of 4 DMRs
on patient DNA samples; 3 DMRs were hypermethylated in AML
versus NBM and one DMR was hypomethylated in AML versus
NBM. The bisulfite results confirmed the MeDIP-seq data for
each region (Fig. S9, Table S7). In addition, we carried out
bisulfite pyrosequencing in 63 AML patients with different
cytogenetic features, 7 AML cell lines [Kasumi (in duplicates),
OCI-AML2, CTS, HL60, Kmoe2, P31/FUJ, THPI] and 5
NBMs. Pyrosequencing validation was performed on 2 DMRs
discriminating between AML and NBM (DPP6, SPHKAP), 2
DMRs that were hypermethylated in 2 AML subtypes; ST6GAL2
in t(8;21), HHEX in trisomy 8 AML and an AluJb repeat that was
differentially hypomethylated in t(8;21) AML. The results revealed
statistically significant differences in DNA methylation as was
detected by MeDIP-seq (Kruskal-Wallis test followed by Dunn’s
multiple comparison P,0.05) (Fig. S10, Table S8).
Regional DNA methylation and gene expression
We sought to determine the relationship between the methyl-
ation profiles and gene expression in AML patients. Therefore, an
array based gene expression profiling for 6 of the AML samples
that had available RNA was performed. Correlating the gene
expression to corresponding DNA methylation on an average scale
revealed strong significant inverse correlation in promoters (13,690
genes) (Pearson r =20.97, P,0.0001), CGIs (inside the promoters
of 8,745 genes) (Pearson r =20.89, P,0.0001) and their parallel
CGI shores (2 Kb upstream to the transcriptional start site; TSS)
[26] (Pearson r =20.8, P,0.0001) (Figs. 4A–C). The intragenic
interspersed repeats (within the promoters/gene bodies) showed
also significant inverse correlation with gene expression. SINEs
(1,285 intragenic repeats) showed the strongest negative correla-
tion (Pearson r =20.82, P,0.0001) followed by LTRs (541
intragenic repeats) (Pearson r =20.63, P= 0.001) and finally
LINEs (11,242 intragenic repeats) (Pearson r =20.54, P= 0.006)
(Figs. 4D–F). This analysis revealed that the gene expression was
strongly correlated with DNA methylation of the promoters, which
is consistent with the accepted role of DNA methylation around
TSS on related gene expression [27,28,29,30]. However, this does
not exclude the importance of some individual CGIs located
outside the promoters in altering nearby gene expression [31,32].
Furthermore, we investigated the relationship between differ-
ential gene expression and DNA methylation by integrating our
promoter MeDIP-seq data with published gene expression data
[33,34,35]. We questioned whether promoter DNA methylation
was associated with the distinctive over and under expressed genes
in each AML subtype. There was significant promoter DNA
methylation difference between the distinctive expressed genes in 3
AML subtypes; t(8;21) AML, NK AML and trisomy 8 AML
(Mann Whitney test, P = 0.005, P= 0.04, P = 0.01 respectively)
(Fig. 4G, Tables S9, S10). This indicates that differential gene
expression was correlated with differential promoter DNA
methylation in most AML subtypes. It was notable in this analysis
that the t(15;17) subgroup did not exhibit this correlation
suggesting additional modifying factors may affect gene expression
in this subgroup.
Down regulation of candidate methylated genes in AML
and AML subtypes
To investigate the consequence of promoter methylation, the
expression of 3 of the genes with the most consistent methylated
promoters in AML was performed i.e. DPP6 (absolute methyla-
tion difference = 0.46, P = 0.0007), SPHKAP (absolute methyla-
tion difference = 0.45, P= 0.0002) and ID4 (absolute methylation
The Methylome of Acute Myeloid Leukemia
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difference = 0.28, P= 0.003). The analysis was performed in 30
AML patients (including 4 AML patients who were previously
involved in MeDIP-seq experiment), cancer cell lines and normal
tissues using real time RT-PCR. The results showed that DPP6,
SPHKAP and ID4 were down regulated in AML patients
(Figs. 5A.1, B.1, C.1). By contrast, DPP6, SPHKAP and ID4 were
expressed in normal tissues. In addition, SPHKAP was down
regulated in cancer cell lines investigated, while the expression of
DPP6 and ID4 was variable among cancer cell lines. Next, we
tested the effect of a demethylating drug [DAC (5-aza-29-
deoxycytidine)] on the expression of both SPHKAP and DPP6
genes in 2 AML cell lines (OCI-AML2 and CTS). This confirmed
that the demethylating treatment was able to restore the
expression of both genes (Figs. 5A.2, B.2).
Since, the HHEX gene (also known as PRH gene) showed a
significant methylated CGI located in its gene body (between exon 2
and exon 3) in trisomy 8 AML against the rest of the groups
(absolute methylation difference= 0.74, P= 961026) (Dataset S3),
we validated the DNAmethylation of that island by pyrosequencing
(Fig. S10d). This demonstrated a significant methylation difference
between trisomy 8 AML and t(8;21) AML (Kruskal-Wallis test
followed Dunn’s multiple comparison tests P,0.5) (Fig. S11a). Next,
we investigated HHEX gene expression by RT-PCR. HHEX gene
showed a significant expression difference among AML subtypes
with a significant expression difference being detected between
trisomy 8 AML and t(8;21) AML (Kruskal-Wallis test followed
Dunn’s multiple comparison tests P,0.5) (Fig. S11b). Correlating
the pyrosequencing results with HHEX gene expression showed a
moderate but significant inverse correlation between the identified
CGI methylation and related gene expression (Spearman r=20.5,
P= 0.004). Treating CTS and OCI-AML2 cell lines with DAC
showed an increase in HHEX gene expression (Fig. S11c). Notably,
fromMeDIP-seq results, there was no DMR identified among AML
subtypes in the promoter of HHEX gene; HHEX promoter
methylation was less than 0.2 Batman score in all MeDIP-seq
samples including trisomy 8 AML.
Discussion
We have used MeDIP-seq to establish the global methylome for
AML. The comprehensive nature of this study (12 independent
primary tumors) has allowed us to investigate the potential
Figure 3. Hierarchical clustering of AML versus NBM in the interspersed repeats. In each figure, each column represents AML patient/NBM
and each row represents a single DMR. First row represents cluster analysis of all AMLs versus all NBMs and the second row represents cluster analysis
of AML subtypes in SINEs (A, D), LINEs (B, E) and LTRs (C, F). Distinctive hypomethylated SINEs, LINEs and LTRs clearly distinguished each AML subtype
(second row).
doi:10.1371/journal.pone.0033213.g003
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epigenomic role of not only gene promoters but also genomic
elements, including CGIs and repeated elements. It is possible to
draw some general conclusions from this study. Firstly, comparison
of the whole genome methylation of the leukemia with the controls
showed that leukemic DNA was only 2.7% less methylated. This
contrasts with the generally held view that cancer is characterized
by global hypomethylation amounting to a 10%–20% difference
[14,36]. It may be that this limited global hypomethylation is a
particular feature of AML. However, a recent MeDIP-seq study of
pooled DNA from peripheral nerve sheath tumors also indicated a
global DNA methylation change of only 0.7% in malignancy
compared to normal [12]. A second general conclusion is that
leukemia specific methylation extends into regions that are not
specifically associated with gene promoters. We similarly found
that AML subtype specific methylation extended beyond gene
promoters and encompassed other genomic features.
Previous genome wide epigenetic studies in leukemia have, for
technical reasons, focused on gene promoters and/or CGIs
[37,38]. Our identification of AML subtype methylation patterns
effectively confirms previous observations [38] that convincingly
demonstrated AML subtype specific methylation of gene promot-
ers. It was of interest to compare our MeDIP-seq results for the
t(8;21) and t(15;17) AMLs to those obtained in that study [38]. We
found 48 genes with the same methylation status observed by
Figueroa and colleagues who used a different technique; (HELP
technique: HpaII tiny fragment Enrichment by Ligation-mediated
PCR) [39]) (Tables S11, S12). Despite the methodological
differences between the two studies it was significant that a
common list of genes could be readily identified.
Although our study did not include all possible subtypes of AML
it did robustly identify specific methylation targets that were
confirmed in a larger series of AML samples using pyrosequencing
technology. Amongst the novel targets identified in this study the
frequent methylation of the promoter of the gene (SPHKAP)
encoding sphingosine kinase anchoring protein in AML was of
particular interest since SPHKAP was down regulated in both AML
patients and cancer cell lines. The SPHKAP protein was identified
through its interaction with and regulation of SPHK1 activity [22].
Additionally, SPHKAP (or SKIP; SPHK1-interactor protein) was
recently identified as a member of A-kinase-anchoring proteins
(AKAPs) [40]. SPHK1 catalyses the phosphorylation of sphingosine
to sphingosine-1-phosphate (S1P) which promotes cell survival and
proliferation [23]. SPHK1 is overexpressed in a range of cancers and
has been proposed as a novel target for cancer therapeutics [41].
The possible leukemogenic role of loss of expression of SPHKAP and
resultant effects on the lipid signaling pathways remains unclear.
However, it is of interest to note that expression of the RUNX1 gene,
which is involved in the t(8;21) translocation in AML, has recently
been linked to regulation of key enzymes involved in sphingolipid
metabolism [42].
The second novel promoter associated DMR, which appeared
in our study to be down regulated in AML patients, was the DPP6
Figure 4. Correlation between DNA methylation and gene expression. (A–F) For a single AML patient we categorized the gene methylation
into 4 groups (.0.4, 0.4–0.6, 0.6–0.8, .0.8 Batman scores). We correlated the average of each methylation group to corresponding average of gene
expression. (G) Box plots of DNA methylation levels of over- and under-expressed genes in each triplicate of t(8;21), t(15;17), NK and trisomy 8 AML
subtypes. N refers to the number of genes in each set. Mann Whitney test of the two sets of genes demonstrated a significant methylation difference
between the medians in t(8;21), NK and trisomy 8 AML subtypes.
doi:10.1371/journal.pone.0033213.g004
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gene. The DPP6 gene was reported as a hypomethylated gene in
colon cancer [26] and at the same time is considered as a
biomarker for melanoma [21]. DPP6 gene became hypermethy-
lated in some tumors and hypomethylated in other types of tumors
as the promoter hypomethylation is important in activation some
oncogenes and in provoking loss of imprinting (LOI) [43].
Since up to 45% of the human genome consists of repetitive
sequences which are not analyzed by array-based methods, it was
desirable to extend the analysis to include such sequences. Our
study suggests that both the hyper- and hypo-methylation of
individual members of the LINE, SINE and LTR families can
readily discriminate AML from NBM. Although we found some
members of the satellite repeat family exhibiting differential
methylation, the discrimination was much less clear. Differences
between satellite methylation and interspersed repeat methylation
were previously reported in leukemia and in bladder cancer [44].
It was also possible to identify repeat family members that
exhibited differential methylation between AML subtypes. As
indicated, very distinct patterns of hypomethylation of members of
the LINE, SINE and LTR appear to be associated with each AML
subtype. Many studies have identified hypomethylation of repeat
sequence elements as important in cancer [36,43]. For example,
hypomethylation of LINEs has been observed in several cancer
types and appears to increase with the degree of malignancy [45].
Hypomethylation of LINEs has also been associated with the
phases of chronic myeloid leukemia and shown to have prognostic
value [46]. This novel observation of AML subtype specific
hypomethylation highlights the potential role of SINEs, LINEs
and LTRs in the transcription activation [47,48] of genes
important in cancer progression and speciation [46,49]. In
addition, these regions could represent discriminating biomarkers
valuable in AML diagnostics.
The establishment of such high resolution AML methylomes not
only reveals the subtle epigenetic changes involved in leukemogen-
esis but also has potentially important clinical implications. It has
been shown that detection of methylated sequences in clinical
remission for AML has the power to predict relapse risk for those
patients [50]. This study has therefore identified a large number of
potential biomarkers that, in principle, could be used to predict
relapse in AML with even greater statistical power.
Figure 5. SPHKAP, DPP6 and ID4 gene expression in AML. (A.1, B.1, C.1) Relative expression of SPHKAP, DPP6, ID4 (respectively) in AML and
normal tissues. The genes were down regulated in AML patients and in cancer cell lines, while the genes were up regulated in normal tissues. (A.2,
B.2, C.2) Relative expression of SPHKAP, DPP6 and ID4 (respectively) in OCI-AML2 and CTS cell lines before and after treatment by DAC. Gene
expression was restored in most of cell lines treated by DAC.
doi:10.1371/journal.pone.0033213.g005
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Materials and Methods
Clinical samples
We applied MeDIP-seq to 12 AML patients. Diagnosis of
leukemia was based on clinical and morphological features [51].
Median age of AML patients was 38.5 and median blast
percentage was 81% (full details Table S1). Patients’ samples
(peripheral blood or bone marrow) were stored in the tissue bank
of the St Bartholomew’s Hospital after informed written consent
was obtained. The human Kasumi leukemic cell line (ACC: 220),
OCI-AML2 leukemic cell line (ACC: 99), HL60 leukemic cell line
(ACC: 3), Kmoe2 leukemic cell line (ACC: 37), REH leukemic cell
line (ACC: 22) were obtained from the Deutsche Sammlung von
Mikroorganismen und Zellkulturen - DSMZ - (German Collection
of Microorganisms and Cell Cultures). Human CTS leukemic cell
line [52], THPI leukemic cell line [53] and P31/FUJ leukemic cell
line [54], CEM leukemic cell line [55], HD-MY-Z lymphoblastic
cell line [56], DHL lymphoma cell line [57] and WM melanoma
cell line [58] were kindly provided by Dr. Simone Jueliger (Queen
Mary University of London, London, UK). DNA was extracted
using Qiagen DNeasy Blood & Tissue kit according to
manufacturer’s instructions. The ethical approval to access the
stored material and to carry out the study was obtained from East
London and City Research Ethics Committee (ref 10/H0704/65).
MeDIP-seq
Only high quality genomic DNA was subjected to MeDIP-seq
protocol (Text S1) [25,59]. This is based on using a monoclonal
antibody against 5-methylcytosine of previously sonicated DNA.
MeDIP DNA libraries were quantified using RT-PCR and the
Agilent Bioanalyser 2100 to get 10 nanomolar concentration
libraries. The MeDIP libraries were subjected to high-throughput
45 base paired-end sequencing using Illumina Genome Analyzer
(GA-II) [60]. Two different algorithms were used for the alignment
of the generated reads against the reference human genome
(NCBI 36/hg18); Maq (Mapping and Assembly with Qualities)
[61] (http://maq.sf.net/ and Li et al.) and Bowtie [62]. Following
the alignment, the repeated sequences (including PCR duplicates
and reads that mapped to more than one location on the genome)
were filtered from the data. Reads with Maq score of ,10 were
excluded from subsequent analysis. Bowtie rounded the quality
values to the nearest 10. For methylation analysis of the uniquely
aligned reads, the Batman algorithm has been used [11]. Batman
(A Bayesian Tool for Methylation Analysis) algorithm infers the
absolute methylation state for 100 bp windows by estimating local
sequencing read enrichment for methylation taking into account
the varying densities of methylated CpGs across the genome [11].
Batman output is in the form of GFF format, each GFF file
represents a score that is equals the median of methylation states in
a 100 bp window. The score ranges between 0–1 according to the
level of methylation. The sequencing data are available in GEO,
accession number: GSE28314
MeDIP-seq data statistical workflow
Quantile normalization was performed to reduce the possible
variations among the laboratory assays and to facilitate the
comparison of the genes across all the samples. This method is
based upon the concept of quantile-quantile plot extended to n
dimensions (where n is the number of samples) [63]. In order to
reduce the complexity of the normalized data, we excluded the
genes in which the difference between the maximum and
the minimum methylation values is lower than the mean of the
standard deviation values of this genomic feature across all the
samples. We next used empirical Bayes statistics provided by
Bioconductor’s limma R package to select the top discriminating
genes for each feature [64]. This was performed for every AML
cytogenetic group against other groups including NBM, and for
all AML versus all NBM. The empirical Bayes model was used to
compute moderated t-statistics and F-statistic. The Benjamini and
Hochberg false discovery rate (FDR) was used as a multiple
testing correction generating adjusted P value for each gene.
However, due to small sample size, not many genes remained
statistically significant when multiple testing corrections were
applied. The frequency of uncorrected P values,0.05 for
differential methylation was higher than expected assuming a
random distribution. This uncorrected P value distribution
indicates a differential methylation pattern between specified
groups (Fig. S12) [65].
DMR
DMR was defined as a differential methylated region with
uncorrected P,0.05 and an absolute methylation difference
.0.25 Batman score (equal to at least 25% difference in DNA
methylation). This threshold was defined using the distribution of
absolute differences in methylation (Batman) scores of all covered
genomic features (618,556) between normal and leukemic samples
(Fig. S13). Since the 99th percentile of the differences in
methylation scores corresponds to 0.23, the minimal difference
in methylation between groups required for calling DMRs was
rounded to 25%. In order to estimate FDR in the DMR calling, a
mixture model approach was used [66]. DMR identification based
on P value,0.05 and absolute methylation difference .25% gave
an FDR of 2.4% across investigated genomic features and repeats,
that was comparable to results obtained by a recent MeDIP-seq
study [12].
Cluster analysis
Hierarchical clustering and pair-wise comparison were formed
using Pearson correlation coefficient to construct the distance
matrix among samples together with ‘Ward’ linkage clustering
method [67]. In order to reduce the data for clustering purposes,
we selected DMRs with P value,0.001 for which we noticed
particular enrichment (Fig. S13).
Whole genome analysis
For the comparison of the whole genome methylation between
AML and NBM, we have categorized DNA methylation into 5
groups and used Fisher’s exact test provided with R to investigate
if there was a statistically significant difference in the global DNA
methylation [64].
Repeats
Repeated regions were obtained from nested RepeatsRM327
table downloaded from UCSC genome annotation database
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/).
Direct Bisulfite sequencing
500 ng genomic DNA was bisulfite converted using EZ DNA
methylation TM kit (Zymo research). PCR amplification of the
bisulfite converted DNA was performed through 42 cycles at 55uC
annealing temperature, the primers used for the PCR are provided
in Table S13. Amplified products were cloned using the TOPO
TA cloning (Invitrogen, TOPO TA cloning kit) and 5–10 clones
were picked for template-amplification of DNA and further
sequencing. Only .95% bisulfite converted clones were analyzed
using QUMA (quantitative method for methylation analysis,
http://qmua.cdb.riken.jp).
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Bisulfite pyrosequencing
500 ng genomic DNA was bisulfite converted using EZ-96
DNA kit TM (Zymo research) specified by the manufacturer. The
converted DNA was PCR amplified using primers for each set of
genes; the primers were designed using PyroMark Assay design 2.0
(primers provided in Table S14). The pyrosequencing was
performed according to a published protocol [68] using PSQ 96
MA (Qiagen) to get a percent methylation at a single CpG site.
The percent methylation at each CpG was calculated using
PyroQ-CpG 1.0.9.
Illumina Infinium array
500 ng genomic DNA was bisulfite converted and hybridized
onto Illumina Infinium HumanMethylation 27 BeadArrays
according to the manufacturer’s protocol [69]. The GenomeStu-
dio Software was used for methylation analysis. As Illumina
Infinium array confined single CpG in ,124 bp, we determined
from MeDIP-seq a 100 bp window that includes this CpG in its
centre. Correlating the average Batman score with each 1%
Infinium array bin revealed a strong correlation between both
methods (Fig. S2).
Array based gene expression profiling
Good quality RNA was available for 6 AML patients involved
in MeDIP-seq experiment. Total RNA of AML patient samples
was extracted from a total of 10–206106 thawed cells using Trizol
(Gibco-BRL) purification method. The Applied Biosystems
Human Genome Survey Microarray (P/N 4337467) was used
for the expression profile [70]. The microarrays contain 31,700
60-mer oligonucleotide probes representing 29,098 individual
human genes, and uses chemiluminescence (CL). cRNA target
preparation and array hybridisation were performed according to
the manufacturer’s protocol (P/N 4339629). Signal intensity, S/N
ratio (signal to noise ratio), and flags values for each array were
extracted. If S/N was greater than 3, it was concluded that the
signal detected was (confidence of 99.9%) a function of the gene
expression levels detected by the probe. For those probes that have
flags value above 5,000, the signals are considered missing values.
The signal values were log2 transformed and normalized across
arrays with quantile normalizaiton method after control probes
were removed. The S/N ratio was used as filtering criteria. All the
statistical analysis was performed with the statistical language R
(http://www.R-project.org). The array expression data has been
deposited in a MIAME compliant database GEO accession
number: GSE34722, (MeDIP-seq study No. 1; GSM853941,
MeDIP-seq study No. 3; GSM854020, MeDIP-seq study No. 4;
GSM854034, MeDIP-seq study No. 5; GSM854005, MeDIP-seq
study No. 8; GSM853976, MeDIP-seq study No. 9;
GSM854019).
RT-PCR
We carried out RT-PCR starting with total RNA (1 mg) for
cDNA synthesis using random primer with Superscript III reverse
transcriptase performed as per the manufacturer’s instructions
(Invitrogen). Maximum cDNA concentration was used in a
volume of 10 ml per run. Real time was carried out using Taqman
universal master mix II as per the manufacturer’s instructions [71].
The maximum amount of RNA was used as per the manufactur-
er’s instructions. Reactions were run on the ABI 7900HT fast Real
time PCR using 96-well plate and the standard thermal cycler
protocol with 40 cycles. Control normal adult RNA was obtained
from Agilent genomics. Normal breast RNA was used to compare
the results in SPHKAP, DPP6 and ID4. Normal lymph node was
run on every plate to ensure the consistency across the runs. 18s
RNA acquired from ABI was used as the endogenous control. All
primers were designed and generated by ABI.
Treatment of cells with 5-aza-29deoxycytidine (DAC)
Twenty-four hours before adding 5-aza-29 deoxycytidine (DAC)
(Sigma), 16106 AML cell line cells were maintained in culture
containing RPMI-1640 with 10% FBS. Cells were treated by DAC
through adding freshly prepared 5 mM DAC in dimethylsulfoxide
(DMSO) to the standard media. DAC treatment was repeated at
48 hours. Control cell lines were treated identically except that
they were treated with standard media to which DMSO only had
been added. We assayed the cells for gene expression 72 hours
after the treatment.
Supporting Information
Text S1 Supporting method MeDIP-seq protocol.
(DOC)
Figure S1 Saturation analysis of MeDIP-seq samples (a,
b, c) The saturation analysis investigates whether the number of
unique reads is sufficient to generate a saturated and reproducible
methylation profile of the reference genome. The higher Pearson
correlation r the greater assurance of the reproducibility of the
methylation profiles. Sample study number is identified in Table
S1.
(DOC)
Figure S2 Correlation between MeDIP-seq and Illu-
mina Infinium array. A significant positive correlation was
found between MeDIP-seq and Illumina Infinium array in the
three MeDIP-seq samples.
(DOC)
Figure S3 Pair-wise comparison between AML and
NBMs in 4 genomic regions. Red colored spots indicate high
similarity and white colored spots low similarity. CGIs (C) showed
the highest similarities between AML subtypes and a clear
discrimination from NBMs. (A) Promoters, (B) Gene bodies, (D)
CGI shores.
(DOC)
Figure S4 Estimating the number of clusters in data set
consisting of differentially methylated CGIs using
prediction strength method The consecutive number of
clusters is given on the x-axis. The vertical bars illustrate the
standard error of the prediction strength over 5 cross-validation
folds. Prediction strength above 0.8 indicates well-separated
clusters. Dividing the CGI associated DMRs data set into two
clusters, referring to AML and NBM groups, gives the highest
stability.
(DOC)
Figure S5 Characters of DMRs in AML subtypes. Venn
diagrams showed few overlapped DMRs between AML subtypes
with no common DMRs detected between the all 4 AML
subtypes.
(DOC)
Figure S6 Pair-wise comparison between AML subtypes
in 4 genomic regions. t(8;21) AML subtype is discriminated
distantly from all the other AML subtypes. (A) Promoter, (B) gene
bodies, (C) CGIs, (D) CGI shores.
(DOC)
Figure S7 Pair-wise comparison between AML and
NBMs in repeat sequences. (A) SINEs showed the highest
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similarities between AML subtypes among other repeats; (B)
LINEs and (C) LTRs.
(DOC)
Figure S8 Pair-wise comparison between AML subtypes
in repeat sequences. There was clear discrimination between
AML subtypes in (A) SINEs, (B) LINEs and (C) LTRs.
(DOC)
Figure S9 Direct bisulfite sequencing of significant
differentially methylated genes/genomic regions in
MeDIP-seq samples. (a, b, c, d, e) For all figures, the horizontal
line represents the position of each CpG investigated and the
vertical line is the percentage of the methylation at particular CpG
site from 0–100%. The analysis was performed using QUMA.
(DOC)
Figure S10 Pyrosequencing results of candidate geno-
mic regions in AML patients, AML cell lines and NBMs.
(a) SPHKAP, (b) DPP6, (c) ST6GAL2, (d) HHEX and (e) Alu repeat.
N refers to the number of samples tested for each investigated
genomic region. Kruskal-Wallis test showed significant methyla-
tion difference among the groups (P,0.0001) for all tested genes
and repeat. Dunn’s multiple comparison tests showed that there
was significant methylation difference between AML patients and
NBMs in SPHKAP and DPP6 (P,0.05). Also, there was significant
methylation difference between AML samples and AML cell lines
in all investigated genes (P,0.05) except in the repeat.
(DOC)
Figure S11 HHEX gene methylation and expression
assay. (a) HHEX gene methylation (a significant methylated
CGI located within the body of HHEX gene) among different
AML patients. (b) HHEX gene expression among different AML
patients. (c) Effect of DAC on HHEX expression in AML cell lines.
HHEX gene expression was measured relative to NBM, PB=per-
ipheral blood from healthy donors.
(DOC)
Figure S12 Histograms of uncorrected P values after
testing the equality of the methylation means between
groups. (a) in 4 genomic regions and (b) in repeats. When
investigating the data with equal means between groups, the P
values were expected to be uniformly distributed across the unit
interval (blue line). Comparing the distribution of uncorrected P
values to the uniform distribution expected for random data revealed
enrichment of P value,0.05 (red line) indicating differential
methylation pattern. Satellites did not show a specific distribution
of uncorrected P values across the samples. High frequencies of P
values,0.05 across the samples were observed in the other tested
repeats; SINEs, LINEs and LTRs.
(DOC)
Figure S13 Histogram illustrating the distribution of
uncorrected P values after testing equality of methylation
between normal and leukemic samples for all genomic
features and repeats. For random data the distribution is
expected to be uniformly distributed across the unit interval (blue
horizontal line). The frequency of P values,0.05 (red line) is higher
than expected with particular enrichment of P values,0.001.
(DOC)
Table S1 Patients and control samples.
(DOC)
Table S2 Criteria of reads generated from Illumina
GAII,
(DOC)
Table S3 Description of the genomic regions from
MeDIP-seq results.
(DOC)
Table S4 DMRs identified in AML versus NBM in 4
genomic regions.
(DOC)
Table S5 DMRs identified in AML subtypes in 4
genomic regions.
(DOC)
Table S6 DMRs associated with repeats. (a, b) AML versus
NBM, (c) between AML subtypes.
(DOC)
Table S7 Direct bisulfite sequencing validation of
selected genomic regions.
(DOC)
Table S8 Pyrosequencing validation of selected geno-
mic regions. (a) AML versus NBM, (b) in AML subtypes.
(DOC)
Table S9 DNA methylation of over- and under ex-
pressed genes in t(8;21), t(15;17) & NK AML subgroups
that were included in MeDIP-seq experiment.
(DOC)
Table S10 DNA methylation of over- and under ex-
pressed genes in trisomy 8 AML subgroup that was
included in MeDIP-seq experiment.
(DOC)
Table S11 The overlapped genes between the results of
MeDIP-seq study and array-based study for t(15;17)
AML.
(DOC)
Table S12 The overlapped genes between the results of
MeDIP-seq study and array-based study for t(8;21) AML.
(DOC)
Table S13 Direct bisulfite sequencing primers.
(DOC)
Table S14 Pyrosequencing primers.
(DOC)
Dataset S1 Differentially methylated promoters.
(XLS)
Dataset S2 Differentially methylated gene bodies.
(XLS)
Dataset S3 Differentially methylated CGIs.
(XLS)
Dataset S4 Differentially methylated CGI shores.
(XLS)
Dataset S5 Differentially methylated SINEs.
(XLS)
Dataset S6 Differentially methylated LINEs.
(XLS)
Dataset S7 Differentially methylated LTRs.
(XLS)
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